Pfizer settles with generic drugmakers to protect blockbuster drug until 2031
BioSpace
The settlements delay the entry of generic copies of Pfizer's Vyndamax by almost three years, stabilizing sales of a drug that generated $3.8 billion in the U.S.
pharminent
April 29, 2026 (Last updated: April 29, 2026)
BioSpace
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug that generated $3.8 billion in the U.S.
